At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 413 enrolled
Drug / intervention
Netupitant and Palonosetron +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multicenter, Randomized, Double-blind, Unbalanced (3:1) Active Control Study to Assess the Safety and Describe the Efficacy of Netupitant and Palonosetron for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy Cycles.
In Brief
A Phase 3 clinical trial evaluating Netupitant and Palonosetron, Aprepitant, and 2 other interventions for Chemotherapy-Induced Nausea and Vomiting. Completed, enrolled 413 participants across 75 sites in 10 countries.
Detailed Summary
NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone. The objective of the study is to evaluate if netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChemotherapy-Induced Nausea and Vomiting
CountriesBulgaria, Czechia, Germany, Hungary, India, Poland, Russia, Serbia, Ukraine, United States
CollaboratorsParexel
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartJul 2011
Primary CompletionSep 2012
TodayJul 2026
First PostedJun 20, 2011
Enrollment StartJul 1, 2011
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 15.0 years ago
Interventions
Netupitant and Palonosetrondrug
Aprepitantdrug
Palonosetrondrug
Dexamethasonedrug